{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-006713","form_type":"8-K","ticker":"TNYA","cik":"0001858848","company_name":"Tenaya Therapeutics, Inc.","filed_at":"2023-03-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.211320+00:00","generated_at":"2026-06-18T08:52:38.948588+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Tenaya Therapeutics FY2022 net loss $123.7M; TN-201 IND cleared, Phase 1b Q3 2023","bullets":["Net loss of $33.5M ($0.61/share) in Q4 2022 and $123.7M ($2.76/share) in FY2022.","Cash and investments $204.2M at year-end; runway expected into first half 2025.","TN-201 IND for MYBPC3 gene therapy cleared by FDA; Phase 1b dosing planned Q3 2023.","TN-301 MAD stage dosing commenced; Phase 1 data from SAD/MAD expected H2 2023.","TN-401 (PKP2 gene therapy) IND submission planned for H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-006713","json":"https://secwatch.observer/filing/0000950170-23-006713.json","markdown":"https://secwatch.observer/filing/0000950170-23-006713.md","text":"https://secwatch.observer/filing/0000950170-23-006713.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858848/000095017023006713/0000950170-23-006713-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858848/000095017023006713/tnya-20230308.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T08:52:38.948588+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3ede02afb95af124ddf2ff07bbd6db7ad680361f","claim":"Tenaya Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2022 results: net income Net loss was $33.5 million, or $0.61 loss per share for the fourth quarter ended December 31, 2022. For the full year 20.","evidence_excerpt":"Tenaya Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858848/000095017023006713/0000950170-23-006713-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2022"},{"label":"Net income","value":"Net loss was $33.5 million, or $0.61 loss per share for the fourth quarter ended December 31, 2022. For the full year 20"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}